1
Home
Companies

NRx Pharmaceuticals

#9565

Rank

$59.13M

Marketcap

US United States

Country

NRx Pharmaceuticals
Leadership team

Dr. Jonathan C. Javitt M.D., M.P.H. (Co-Founder, Chief Scientist & Director)

Mr. Robert Besthof M.I.M. (Head of Operations, Chief Commercial & Patient Officer)

Mr. Stephen H. Willard Esq. (CEO & Director)

Products/ Services
Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
Headquarters
Wilmington, Delaware, United States
Established
2015
Company Registration
SEC CIK number: 0001719406
Traded as
NRXP
Social Media
URL
https://www.nrxpharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
History

Founded in 2011, NRx Pharmaceuticals is a biopharmaceutical research and development company focused on bringing innovative and cost-effective treatments to difficult-to-treat diseases. We strive to overcome challenges in drug development by leveraging our research capabilities and cutting-edge technologies. Through clinical trials, we actively seek out new ways to optimize patient care and improve safety and efficacy.

Mission
Our mission is to develop novel treatments that will contribute to improved patient outcomes and significantly improve the quality of life for patients around the world.
Vision
Our vision is to be the global leader in biopharmaceutical innovation and partnering with pharmaceutical and biotechnology companies to deliver transformational treatments.
Key Team

Prof. Daniel C. Javitt (Co-Founder & Chairman of Scientific Advisory Board)

Dr. Seth L. Van Voorhees Ph.D. (CFO & Treasurer)

Suzanne Messere (Investor Relations)

Dr. Philip T. Lavin Ph.D. (Chief Methodologist)

Dr. Michael Kunz (Gen. Counsel & Corp. Sec.)

Dr. Dennis K. McBride Ph.D. (Chief Strategy Officer & Sr. Scientist)

Ms. Molly Cogan (Sr. Director of Global Communications & Gov. Affairs)

Recognition and Awards
NRx has received the following awards for its excellence in drug research and development: Fast Company's Innovators of the Year 2019; Pharma Innovator Award winner 2018; Pharmaceutical Loyalty Award 2018; Pharmaceutical Research and Development Excellence Award 2018; Pharma Partner Award 2018.
References

https://in.investing.com/equities/big-rock-partners-o

https://finance.yahoo.com/quote/NRXP/profile?p=NRXP

https://www.crunchbase.com/organization/neurorx

https://companiesmarketcap.com/

https://www.nrxpharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

NRx Pharmaceuticals
Leadership team

Dr. Jonathan C. Javitt M.D., M.P.H. (Co-Founder, Chief Scientist & Director)

Mr. Robert Besthof M.I.M. (Head of Operations, Chief Commercial & Patient Officer)

Mr. Stephen H. Willard Esq. (CEO & Director)

Products/ Services
Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
Headquarters
Wilmington, Delaware, United States
Established
2015
Company Registration
SEC CIK number: 0001719406
Traded as
NRXP
Social Media
URL
https://www.nrxpharma.com